Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a ...

Viking Therapeutics VKTX is set to report fourth-quarter and full-year 2024 earnings on Feb. 5, after market close. Since the ...

A couple of months ago, healthcare equity research analyst Jared Holz from Mizuho spoke about Viking potentially being an acquisition target. During his discussion, Holz suggested that Viking could ...

Another option is to invest in the developers of promising, yet-to-be-released obesity drugs, such as Amgen Inc. (AMGN), Viking Therapeutics Inc. (VKTX), and Structure Therapeutics Inc.

Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has set terms for an upsized $275M initial public offering. In a recent SEC filing, Metsera (MTSR ...

Please provide your email address to receive an email when new articles are posted on . Obesity drug prescriptions rose from 760,000 in July 2017 to 1.51 million in February 2024. Phentermine was ...

VKTX had previously announced plans to file an investigational new drug (IND) application for this candidate in obesity indication before this year’s end. We also expect management to provide an ...

TOKYO -- After a year of record profits, Japan's Chugai Pharmaceutical is riding high in the stock market on hopes for an obesity drug under development, but its prospects could be dimmed if Robert F.

Shares of newly public Metsera (NASDAQ:MTSR), which is developing ultra-long-acting obesity drugs, rallied 54% following a $275M initial public offering. Metsera (NASDAQ:MTSR) shares opened at $25 ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...